Merus N.V. (MRUS) and PolarityTE Inc. (NASDAQ:PTE) Contrasting side by side – The Broch Herald

Since Merus N.V. (NASDAQ:MRUS) and PolarityTE Inc. (NASDAQ:PTE) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation of both companies.

Earnings and Valuation

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Merus N.V. and PolarityTE Inc.

Profitability

Table 2 provides Merus N.V. and PolarityTE Inc.s return on equity, net margins and return on assets.

Liquidity

Merus N.V.s Current Ratio and Quick Ratio are 6.4 and 6.4 respectively. The Current Ratio and Quick Ratio of its competitor PolarityTE Inc. are 5.6 and 5.6 respectively. Merus N.V. therefore has a better chance of paying off short and long-term obligations compared to PolarityTE Inc.

Analyst Recommendations

Merus N.V. and PolarityTE Inc. Ratings and Recommendations are available in the next table.

Merus N.V. has a 27.47% upside potential and an average price target of $20. Meanwhile, PolarityTE Inc.s average price target is $9.5, while its potential upside is 197.81%. Based on the analysts opinion we can conclude, PolarityTE Inc. is looking more favorable than Merus N.V.

Institutional & Insider Ownership

Institutional investors held 65.8% of Merus N.V. shares and 45.6% of PolarityTE Inc. shares. 30.47% are Merus N.V.s share held by insiders. Competitively, 33% are PolarityTE Inc.s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Merus N.V. has 12.5% stronger performance while PolarityTE Inc. has -64.71% weaker performance.

Summary

PolarityTE Inc. beats on 6 of the 11 factors Merus N.V.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer. Its pre-clinical bispecific antibody candidates include MCLA-134 and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Incyte and ONO Pharmaceutical Co., Ltd. to develop bispecific antibody candidates based on Biclonics technology platform. Merus N.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.

PolarityTE, Inc. operates as a biotechnology and regenerative biomaterials company in the United States. The company focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more from the original source:
Merus N.V. (MRUS) and PolarityTE Inc. (NASDAQ:PTE) Contrasting side by side - The Broch Herald